Antibodies News and Research

RSS

Antibody-like proteins derived from sharks may be used to combat future SARS outbreaks

Small, unique antibody-like proteins known as VNARs -; derived from the immune systems of sharks -; can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16.

16 Dec 2021

NIH scientists highlight the urgent need for universal coronavirus vaccines

A growing body of scientific evidence, considered together with ecological reality, strongly suggest that novel coronaviruses will continue to infect bats and other animal reservoirs and potentially emerge to pose a pandemic threat to humans.

16 Dec 2021

New study demonstrates SARS-CoV-2 Omicron antibody escape

A new study examined the neutralization of virus variants using three sets of antibodies: serum from individuals vaccinated or infected with earlier variants of the virus; concentrated human antibodies from plasma donors; and approved monoclonal antibodies.

16 Dec 2021

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

A new study reports the results of a study focused on immune evasion characteristics, specifically the ability to escape neutralization by antibodies to the earlier SARS-CoV-2 variants or to the spike antigen used in COVID-19 vaccines.

16 Dec 2021

Study suggests convalescent plasma appears safe but does not prevent SARS-CoV-2 infection

A new study assesses the safety and efficacy of SARS-CoV-2 convalescent plasma containing high titers of anti-SARS-CoV-2 antibodies as PEP.

16 Dec 2021

Using fungal vaccine to train stem cells and enhance immune response to infections

The research group Immunology of Fungal Infections at the University of Valencia (UV) has investigated a fungal vaccine with which to train stem cells and hematopoietic progenitors (which produce all the cells of the blood and lifelong immune system) to improve the immune response to infections. The work has been published in the journal Frontiers in Immunology.

16 Dec 2021

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

A new study found that the Omicron S protein evades antibodies with a 44-fold higher efficiency than the Delta variant's spike, rendering therapeutic antibodies ineffective and likely negatively impacting antibody protection induced by infection or double vaccination.

16 Dec 2021

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

The team observed that three doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine are required to mount an effective antibody response against the Omicron variant.

16 Dec 2021

Scientists find better treatment options for patients with advanced colorectal cancer

City of Hope, a world-renowned cancer research and treatment organization, today announced study results of a Phase 2 clinical trial showing monotherapy with sotorasib resulted in anti-tumor activity and a favorable benefit-risk profile among heavily pretreated patients with advanced colorectal cancer. The research was published today in Lancet Oncology.

16 Dec 2021

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

A new study has used this assay to evaluate sera, obtained from 239 individuals vaccinated via any of the above-stated vaccines against SARS-CoV-2’s original strain, the Delta, and Omicron SARS-CoV-2 pseudoviruses.

16 Dec 2021

Human monoclonal antibody protects against SARS-CoV-2 and SARS-CoV in vivo

Scientists identified a human monoclonal antibody (mAb), which successfully neutralized or bound all sarbecoviruses tested in vitro.

16 Dec 2021

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

A new study determines the ability of individuals with varying exposure to SARS-CoV-2 infection and vaccination, to neutralize SARS- CoV-2 pseudotypes.

16 Dec 2021

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Researchers from Westmead Hospital have been investigating the effect of a third dose on neutralizing antibody titres in already vaccinated individuals.

16 Dec 2021

Omicron is more transmissible but may have milder symptoms for many people, expert says

If the first reports coming out of South Africa are correct, Omicron might be more transmissible than the current dominant Covid-19 strain, Delta, but cause less severe symptoms for many people. A leading expert says that, if the new strain does turn out to be milder for some people, that creates a new set of problems.

16 Dec 2021

Antibodies News and Research

Antibody-like proteins derived from sharks may be used to combat future SARS outbreaks

NIH scientists highlight the urgent need for universal coronavirus vaccines

New study demonstrates SARS-CoV-2 Omicron antibody escape

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

Study suggests convalescent plasma appears safe but does not prevent SARS-CoV-2 infection

Using fungal vaccine to train stem cells and enhance immune response to infections

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

Scientists find better treatment options for patients with advanced colorectal cancer

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

Human monoclonal antibody protects against SARS-CoV-2 and SARS-CoV in vivo

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Omicron is more transmissible but may have milder symptoms for many people, expert says

Evaluation of SARS-CoV-2 neutralizing antibodies in mothers and infants

Evaluation of SARS-CoV-2 Omicron's immune evasion potential

SARS-CoV-2 VOCs dependent on IFITM2 for efficient infection establishment

Weak T-cell clonal response to SARS-CoV-2 vaccination in IBD patients deficient in antibody-responders

Researchers take advantage of virus' sweet tooth in the design of sugar-coated COVID-19 test strip

T-cell immune response in previously infected and vaccinated individuals effective against SARS-CoV-2 Omicron variant

Antibodies eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News